# TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

> **NCT06001762** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer
- Early-stage Breast Cancer
- High Risk Breast Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Tamoxifen
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** LHRH Agonist

## Key facts

- **NCT ID:** NCT06001762
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-05
- **Primary completion:** 2025-01-22
- **Final completion:** 2027-01-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001762, "TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06001762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*